Trial Profile
An Open-label Phase 2 Study to Assess the Effect of C5aR Antagonist Therapy by CCX168 Oral Administration on ex Vivo Thrombus Formation and Disease Activity in ESRD Patients With Atypical Hemolytic Uremic Syndrome
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Avacopan (Primary)
- Indications Atypical Haemolytic Uraemic Syndrome
- Focus Proof of concept; Therapeutic Use
- Acronyms ACCESS
- Sponsors ChemoCentryx
- 02 Mar 2017 Status changed from recruiting to discontinued.
- 07 Nov 2016 According to ChemoCentryx media release, the company has announced positive data (n=5) from this pilot phase II trial.
- 08 Aug 2016 According to a ChemoCentryx media release, the company expects to report early results from this trial in late 2016.